Edition:
United States

KemPharm Inc (KMPH.OQ)

KMPH.OQ on NASDAQ Stock Exchange Global Market

2.40USD
20 Nov 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.40
Open
$2.52
Day's High
$2.60
Day's Low
$2.37
Volume
17,649
Avg. Vol
42,292
52-wk High
$8.35
52-wk Low
$2.01

Latest Key Developments (Source: Significant Developments)

Kempharm Q3 Loss Per Share $0.94
Thursday, 8 Nov 2018 04:05pm EST 

KemPharm Inc ::KEMPHARM, INC. REPORTS THIRD QUARTER 2018 RESULTS.Q3 LOSS PER SHARE $0.94.Q3 EARNINGS PER SHARE VIEW $-0.77 -- THOMSON REUTERS I/B/E/S.  Full Article

KemPharm Enters Into License Agreement With KVK Tech
Tuesday, 30 Oct 2018 04:05pm EDT 

Oct 30 (Reuters) - KemPharm Inc ::KEMPHARM ENTERS INTO LICENSE AGREEMENT WITH KVK TECH FOR THE COMMERCIALIZATION OF APADAZ®.KEMPHARM INC - TO RECEIVE UP TO AN ESTIMATED $3.4 MILLION IN PRE-LAUNCH PAYMENTS AND COST REIMBURSEMENTS.KEMPHARM INC - POTENTIAL TO RECEIVE UP TO AN ADDITIONAL $53 MILLION IN AGGREGATE MILESTONE PAYMENTS TIED TO SPECIFIED NET SALES LEVELS.  Full Article

Kempharm Announces Topline Results From Intranasal Human Abuse Potential Trial Of KP415 Prodrug
Monday, 17 Sep 2018 07:30am EDT 

Sept 17 (Reuters) - KemPharm Inc ::KEMPHARM ANNOUNCES POSITIVE TOPLINE RESULTS FROM INTRANASAL HUMAN ABUSE POTENTIAL TRIAL OF KP415 PRODRUG.KEMPHARM INC - NDA FILING FOR KP415 ANTICIPATED AS SOON AS Q1 2019 FOLLOWING SUCCESSFUL COMPLETION OF HAP PROGRAM.KEMPHARM INC - REMAIN ACTIVELY ENGAGED IN A PARTNERING PROCESS FOR KP415 AND KP484, WHICH CO IS TARGETING FOR COMPLETION BY YEAR-END.KEMPHARM INC - SDX IS NOT EFFICIENTLY CONVERTED TO ACTIVE D-METHYLPHENIDATE WHEN SNORTED.KEMPHARM - MEAN DRUG LIKING (E(MAX)) OF INTRANASAL KP415 PRODRUG (SERDEXMETHYLPHENIDATE) STATISTICALLY SIGNIFICANTLY LOWER THAN D-METHYLPHENIDATE HYDROCHLORIDE.  Full Article

KemPharm Announces Positive Results From Oral Human Abuse Potential Trial Of KP415 Prodrug
Tuesday, 11 Sep 2018 07:30am EDT 

Sept 11 (Reuters) - KemPharm Inc ::KEMPHARM ANNOUNCES POSITIVE TOPLINE RESULTS FROM ORAL HUMAN ABUSE POTENTIAL TRIAL OF KP415 PRODRUG.KEMPHARM INC - MEAN DRUG LIKING OF KP415 PRODRUG AT BOTH 120 MG AND 240 MG DOSES WERE STATISTICALLY SIGNIFICANTLY LOWER THAN FOCALIN XR AT 80 MG.KEMPHARM INC - MEAN DRUG LIKING (E(MAX)) OF KP415 PRODRUG AT 120 MG DOSE WAS STATISTICALLY SIGNIFICANTLY LOWER THAN 60 MG OF PHENTERMINE.KEMPHARM - RESULTS FROM INTRANASAL HAP TRIAL EXPECTED TO BE FINAL COMPONENT OF NDA FOR KP415 WITH FDA, THAT REMAINS ON TRACK FOR SUBMISSION IN Q1 2019.  Full Article

Kempharm Q2 Loss Per Share $0.91
Thursday, 9 Aug 2018 04:05pm EDT 

KemPharm Inc ::KEMPHARM, INC. REPORTS SECOND QUARTER 2018 RESULTS.Q2 LOSS PER SHARE $0.91.Q2 EARNINGS PER SHARE VIEW $-0.96 -- THOMSON REUTERS I/B/E/S.REMAIN WELL POSITIONED TO FILE A POTENTIAL NEW DRUG APPLICATION FOR KP415 IN EARLY 2019.  Full Article

Kempharm Announces Top Line Results From KP415.E01 Efficacy And Safety Trial In Children With ADHD
Monday, 9 Jul 2018 07:00am EDT 

July 9 (Reuters) - KemPharm Inc ::KEMPHARM ANNOUNCES TOP LINE RESULTS FROM KP415.E01 EFFICACY AND SAFETY TRIAL IN CHILDREN WITH ADHD.KEMPHARM INC - RESULTS FROM TRIAL (KP415.E01) INDICATED THAT KP415 SUCCESSFULLY MET PRIMARY EFFICACY ENDPOINT.KEMPHARM INC - KP415 WAS GENERALLY WELL-TOLERATED WITH ADVERSE EVENTS (AES) TYPICAL OF STIMULANT THERAPY.KEMPHARM - ANTICIPATE DEVELOPING ADDITIONAL CLINICAL DATA FOR KP415 THROUGHOUT 2018, INCLUDING COMPLETION OF ONGOING ORAL & INTRANASAL HUMAN ABUSE POTENTIAL STUDIES.KEMPHARM - COMPLETING ANALYSIS OF FULL DATA SET FROM KP415.E01 TRIAL & OTHER STUDIES WILL ALLOW TO SUBMIT NDA FOR KP415 WITH FDA IN Q1 OF 2019.KEMPHARM INC - SUBJECTS WHO RECEIVED KP415 MET TRIAL'S PRIMARY AND SECONDARY EFFICACY ENDPOINT, SHOWING STATISTICALLY SIGNIFICANT IMPROVEMENT.  Full Article

KemPharm Reports Q1 Loss Per Share $1.77
Thursday, 10 May 2018 04:05pm EDT 

May 10 (Reuters) - KemPharm Inc ::KEMPHARM ANNOUNCES POSITIVE, TOPLINE RESULTS FROM AN INTRAVENOUS HUMAN ABUSE POTENTIAL TRIAL WITH KP415 PRODRUG; REPORTS Q1 2018 RESULTS.Q1 LOSS PER SHARE $1.77.Q1 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.NO STATISTICALLY SIGNIFICANT DIFFERENCE IN MEAN DRUG LIKING E(MAX) BETWEEN KP415 PRODRUG (57 POINTS) AND PLACEBO (54 POINTS).KP415 PRODRUG DEMONSTRATED STATISTICALLY SIGNIFICANT DIFFERENCES COMPARED TO D-METHYLPHENIDATE HYDROCHLORIDE IN PRIMARY ENDPOINT.  Full Article

Kempharm Announces Positive Topline Results From KP415 Pharmacokinetic Study In Children And Adolescents With ADHD
Tuesday, 20 Mar 2018 07:30am EDT 

March 20 (Reuters) - Kempharm Inc ::KEMPHARM ANNOUNCES POSITIVE TOPLINE RESULTS FROM KP415 PHARMACOKINETIC STUDY IN CHILDREN AND ADOLESCENTS WITH ADHD.KEMPHARM INC - ‍ANTICIPATE ADDITIONAL CLINICAL DATA THROUGHOUT 2018, INCLUDING TOPLINE RESULTS FROM ON-GOING PIVOTAL EFFICACY STUDY BY MID-YEAR​.  Full Article

Kempharm Announces FDA Approval Of Apadaz
Friday, 23 Feb 2018 02:00pm EST 

Feb 23 (Reuters) - Kempharm Inc ::KEMPHARM SAYS U.S. FDA APPROVED NDA FOR APADAZ FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE OPIOID ANALGESIC.KEMPHARM SAYS U.S. DRUG ENFORCEMENT ADMINISTRATION INDICATED INTENT TO SCHEDULE APADAZ AS A C-II PRODUCT.KEMPHARM ANNOUNCES FDA APPROVAL OF APADAZ (BENZHYDROCODONE AND ACETAMINOPHEN) FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN.  Full Article

Kempharm Initiates Pivotal Efficacy Trial Of KP415
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Kempharm Inc ::KEMPHARM INITIATES PIVOTAL EFFICACY TRIAL OF KP415.KEMPHARM INC - ENROLLMENT IN TRIAL IS EXPECTED TO TOTAL APPROXIMATELY 140 PATIENTS ACROSS FIVE CLINICAL SITES IN UNITED STATES.  Full Article